PRMT5 and pancreatic ductal adenocarcinoma: <h4>Introduction</h4>PRMT5 inhibitors are under clinical investigation for pancreatic ductal adenocarcinoma (PDAC), but strategies to maximize their therapeutic efficacy remain undefined.